Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty industry, indicating a "Buy" recommendation for several companies within the sector [2][14]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Beauty Care Index rising by 1.5% from July 4 to July 11, 2025, which is below the market average [3][5]. - The introduction of new products in the regenerative medicine sector, particularly in the "童颜针" (youthful needle) category, is expected to enhance consumer interest and expand the market [2][8]. - The report highlights strong anticipated earnings growth for several key companies in the cosmetics sector for the second quarter of 2025, with notable increases in revenue and net profit for brands like 上美股份 (Shangmei), 丸美股份 (Marubi), and 珀莱雅 (Proya) [9][10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing varied performance, such as the Shenwan Cosmetics Index increasing by 2.6% [3][5]. - The report notes that the demand for cosmetics is recovering, with a 4.1% year-on-year increase in retail sales for the first five months of 2025 [19][20]. Company Performance - 上美股份 (Shangmei) is expected to see a revenue increase of 16% and a net profit increase of 25% in the first half of 2025 [10]. - 丸美股份 (Marubi) anticipates a 22% revenue growth and a 28% increase in net profit for the second quarter of 2025 [10]. - 珀莱雅 (Proya) is projected to achieve a 10% revenue growth and a 15% increase in net profit for the second quarter of 2025 [10]. - 毛戈平 (Mao Geping) expects a significant revenue increase of 38% and a net profit increase of 35% in the first half of 2025 [10]. - 若羽臣 (Ruoyuchen) forecasts a remarkable 70% revenue growth and a 75% increase in net profit for the second quarter of 2025 [10]. Market Trends - The report emphasizes the ongoing trend of domestic brands gaining market share, with national brands occupying five of the top ten positions in the skincare market [32]. - The regenerative medicine sector is expanding, with new products enhancing consumer engagement and market growth potential [2][8]. Investment Recommendations - The report recommends focusing on companies with strong brand matrices and high growth potential, such as 上美股份 (Shangmei), 珀莱雅 (Proya), and 丸美股份 (Marubi) [14]. - It suggests monitoring companies that leverage e-commerce and social media platforms effectively, such as 若羽臣 (Ruoyuchen) and 毛戈平 (Mao Geping) [14].

Core Viewpoint - The establishment of the market position evaluation system by the China Fragrance and Cosmetic Industry Association marks a significant shift in the Chinese cosmetics industry, emphasizing brand building and long-term value over mere sales figures [2][3][4]. Group 1: Market Position Evaluation System - The new market position evaluation system aims to promote brand building and support companies that adhere to long-term value principles, rather than simply ranking based on sales [4][5]. - The evaluation system is based on a comprehensive data collection process, including online and offline retail channels, and involves multiple verification steps to ensure accuracy [8][11]. - The system's key indicators include total retail sales (weighted at 70%) and brand accumulation (weighted at 30%), with a strict one-vote veto policy for brands with significant quality issues [11][12]. Group 2: Industry Insights and Trends - The Chinese cosmetics market has maintained a scale exceeding 1 trillion yuan, with projected market sizes of 1,044.55 billion yuan for 2023 and 1,073.82 billion yuan for 2024 [4]. - The top 50 brands accounted for 21.74% of the total retail sales in 2024, with 22 Chinese brands making the list, reflecting the rapid rise of local brands due to their adaptability to online channels [30][32]. - Despite the progress, Chinese brands still face challenges in achieving quality upgrades, as they primarily occupy the lower segments of the market structure [32][33]. Group 3: Industry Response and Future Directions - The release of the evaluation results has generated significant media attention and industry response, with many executives recognizing the importance of brand value in a changing market landscape [15][17][19]. - Companies are focusing on enhancing their brand value through technological innovation, quality control, and organizational evolution, as emphasized by industry leaders [34][35]. - The association aims to create a systematic approach to promote high-quality development across the entire cosmetics industry, advocating for a shift from a "tack" structure to an "olive" structure, which would support the growth of mid-tier companies [33][37].

Core Insights - The report maintains an "outperform" rating for the retail sector, anticipating that easing international conditions and domestic policy stimulus will positively influence the sector's performance [3][42]. - The overall retail sales in May 2025 reached 4.13 trillion, growing by 6.4% year-on-year, with goods retail sales increasing by 6.5% [11][14]. Beauty and Personal Care - In May 2025, the cosmetics retail sales grew by 4.4%, with high online penetration leading to diminishing promotional effects. However, leading domestic brands are expected to outperform the market due to the trend of domestic product substitution [11][12]. - The competitive landscape is intensifying, with rising sales expense ratios expected to pressure profit margins for some brands, although top players with strong product innovation may still achieve robust growth [11][12]. Gold and Jewelry - The gold and jewelry sector saw a significant year-on-year growth of 21.8% in May 2025, benefiting from a low base effect from the previous year. Products that appeal to younger consumers are expected to drive higher growth rates [11][12]. Supermarkets and Department Stores - From January to May 2025, department store sales slightly increased by 1.3%, while supermarket sales grew by 5.7%. Companies that adapt to the current value-for-money consumption trend through supply chain upgrades are expected to perform better [12][14]. Cross-Border E-commerce - The second quarter is expected to face short-term performance pressures due to external environmental challenges. However, leading platform companies are anticipated to demonstrate strong resilience in the medium to long term due to flexible tariff responses and solid product capabilities [12][14]. Investment Recommendations - The report recommends several companies across different sectors, including: - Beauty and Personal Care: Recommended companies include 毛戈平, 丸美生物, and 登康口腔, which are expected to benefit from domestic product substitution and channel optimization [3][42]. - Gold and Jewelry: Companies like 老铺黄金 and 潮宏基 are highlighted for their potential to achieve accelerated growth due to favorable market conditions [3][42]. - Cross-Border E-commerce: Recommended companies include 小商品城 and 安克创新, which are positioned to capitalize on improving trade conditions [3][42]. - Retail: Companies such as 名创优品 and 重庆百货 are suggested for their low valuation and potential for improvement [3][42].

Core Viewpoint - Marubi has established itself as a leading brand in the eye care segment, achieving significant sales milestones and cultural relevance through its annual "Eye Cream Festival" and collaborations with artists, thereby redefining the standards for domestic eye care products [6][19][28]. Group 1: Brand Recognition and Achievements - Marubi was awarded the title of "First Brand in Domestic Eye Care" by the China Fragrance and Cosmetic Industry Association, highlighting its market leadership and brand strength [16][18]. - The brand has maintained the highest sales in the eye care category for three consecutive years, with its flagship product, the small red pen eye cream, achieving sales of 5 billion [18][19]. - In 2024, Marubi's GMV exceeded 900 million, with an impressive growth rate of 83.9%, further solidifying its position as the leading domestic eye care brand [18]. Group 2: Marketing and Cultural Integration - The 12th "Eye Cream Festival" featured a collaboration with contemporary artist Song Santu, emphasizing the integration of art and culture into the brand's marketing strategy [7][10]. - Marubi's marketing approach has evolved from emotional marketing to emotional engagement, creating a deeper connection with consumers through artistic collaborations [12][14]. - The festival has transformed from a promotional event into a cultural ceremony, enhancing brand identity and consumer engagement [27][28]. Group 3: Product Development and Innovation - Marubi has focused on continuous product innovation, launching multiple iterations of its small red pen eye cream, with the latest version featuring a 25% custom high-concentration peptide formula [22][24]. - The brand has developed a comprehensive product matrix, including key products like the small purple eye cream and butterfly eye mask, to enhance its online presence and sales performance [24]. - Marubi's research and development capabilities have evolved into a fourth-generation system, integrating advanced technologies to ensure product efficacy and safety [27]. Group 4: Strategic Positioning and Market Insights - Marubi's strategy emphasizes systematic capabilities, combining product development, marketing, and consumer trust to create a robust competitive advantage in the eye care market [26][28]. - The brand's long-term commitment to quality and innovation has allowed it to build a strong reputation and consumer loyalty in a highly competitive landscape [19][28]. - Marubi's success illustrates that a brand can thrive in the beauty industry without relying on anxiety-driven narratives, focusing instead on product quality and cultural depth [28][29].

Market Performance - The market experienced an upward trend last week, with the CSI Xinhua National Brand Index rising by 1.39% to 1649.96 points [1][2] - The Shanghai Composite Index increased by 1.40%, the Shenzhen Component Index by 1.25%, the ChiNext Index by 1.50%, and the CSI 300 Index by 1.54% [2] Strong Stock Performances - Notable strong performers included Anji Technology, which rose by 7.98%, and WuXi AppTec, which increased by 7.58% [2] - Other significant gainers included Yiling Pharmaceutical, Tiger Med, and AVIC Shenyang Aircraft, all rising over 6% [2] - The overall trend showed many stocks in the index gaining over 1%, indicating broad market strength [2] Year-to-Date Performance - Since the beginning of 2025, notable stock performances include: - Xintai rising by 55.34% - Anji Technology increasing by 45.75% - WuXi AppTec and Marubi both rising over 30% [3] Market Outlook - Analysts from Xing Shi Investment suggest that the market will continue to perform positively due to strong trading sentiment and sector rotation opportunities [4] - The overall risk premium in the A-share market remains at historically low levels, indicating high value [4] - The macroeconomic environment is expected to remain stable, with ongoing domestic policy support and emerging opportunities in sectors like artificial intelligence and new consumption [4][5] Investment Strategy - Wangzheng Asset maintains a strategy focused on "technology blue chips + innovative growth," emphasizing quality of business operations and undervalued stocks in sectors such as internet, electronics, and automotive [5] - The focus is also on high-potential innovative growth sectors as they mature and enter rapid growth phases [5]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of June 27 to July 4, 2025, with the Shenwan Beauty Care Index declining by 0.6% and the Shenwan Cosmetics Index down by 1.5% [3][4]. - Domestic brands such as Maogeping and others showed significant growth, with some achieving over 50% growth in June, which is expected to positively impact Q2 performance [3][9]. - The report highlights a strong performance from leading domestic brands during the 618 shopping festival, with a notable increase in sales momentum post-event [9][10]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 0.6%, while the Shenwan Cosmetics Index fell by 1.5%, indicating weaker performance compared to the Shenwan A Index [4]. - The personal care products index saw a slight increase of 0.7%, but still lagged behind the Shenwan A Index by 0.4% [4]. Key Company Performance - Expected performance for major companies in Q2 includes: - Upbeauty: Revenue and net profit expected to grow by 16% and 25% respectively [11]. - Marubi: Anticipated revenue and net profit growth of 22% and 28% [11]. - Proya: Projected revenue and net profit growth of 10% and 15% [11]. - Maogeping: Expected revenue and net profit growth of 38% and 35% [11]. - Ruifeng: Anticipated growth of 70% and 75% in revenue and net profit respectively [11]. - Juzhibio: Expected growth of 25% and 20% in revenue and net profit [11]. Market Trends - The report notes a robust recovery in consumer demand, with a 4.1% year-on-year increase in retail sales for cosmetics in the first five months of 2025 [20]. - The domestic market is seeing a shift with local brands gaining market share, as evidenced by the performance of brands like Proya and Maogeping during major shopping events [34]. Investment Recommendations - Recommended stocks include: - Upbeauty, Proya, and Marubi for their comprehensive brand matrices and growth potential [15]. - Maogeping and Juzhibio for their strong positioning in niche markets [15]. - Attention is advised for Shanghai Jahwa, Betaini, and Huaxi Biological for potential growth [15]. E-commerce Insights - Data from Douyin indicates significant growth for domestic brands, with Han Shu achieving a GMV of 7.2 billion yuan, reflecting a 53% year-on-year increase [16]. - The overall GMV for domestic brands in June reached over 50% growth, indicating a strong market presence [9][16].

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 2024年年度报告的 信息披露监管问询函回复的核查意见 上海证券交易所: 贵所《关于广东丸美生物技术股份有限公司 2024 年年度报告的信息披露监管 问询函》(上证公函【2025】0714 号)已收悉,中信证券股份有限公司(以下简称 "中信证券"或"保荐机构")作为广东丸美生物技术股份有限公司(以下简称"丸 美生物"或"公司")的持续督导保荐机构,会同公司及相关中介机构,对问询函所 提及的相关事项进行了认真核查落实,现将问询函所涉及问题回复如下,请予审核。 三、关于在建工程 年报披露,公司期末在建工程 6.03 亿元,其中"营销升级及运营总部建设" 6.01亿元,工程进度 90.76%,"化妆品智能制造工厂建设项目"0.72亿元,工程进 度 95. 94%。报告期内公司将上述两项募投项目预定可使用状态日期分别延期至 2026 年 9 月、2025年 12 月,项目进展较为缓慢。现金流量表显示,公司近三年购建固 定资产、无形资产和其他长期资产支付的现金分别为 1. 11 亿元、22.54 亿元、3. 16 亿元。 请公司:(1)补充披露上述项目的具体实施进 ...

关于广东丸美生物技术股份有限公司 2024 年年度报告的信息披露问询函的回复 华兴专字[2025]24012360165 号 华兴会计师事务所(特殊普通合伙) 计师事务所(特殊普 CERTIFIED PUBLIC ACCOUN 东路152号中山大厦B座6-9楼 Add : 6-9/F Block B,152 Hudong Road,Fuzhou,Fujian,China 电话(Tel):0591-87852574 Http://www.fjhxcpa.com 邮政编码(Postcode):350003 关于广东丸美生物技术股份有限公司 2024 年年度报告的信息披露问询函的回复 华兴专字[2025]24012360165 号 上海证券交易所: 由广东丸美生物技术股份有限公司(以下简称"丸美生物"或"公司")转来的 《关于广东丸美生物技术股份有限公司 2024年年度报告的信息披露监管问询函》 (以下简称"间询函")已收悉,华兴会计师事务所(特殊普通合伙)(以下简称"会 计师"或"我们")作为丸美生物 2024 年年报审计机构,就有关涉及会计师说明或 发表意见的问题,进行了认真分析与核查,现根据问询函所涉问题进行 ...